Lumretuzumab
Monoclonal antibody
- none
- 1448327-63-6
- none
- Y6M3205516
- D11239
Lumretuzumab (INN; development code RG7116) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
This drug was developed by Genentech/Roche.
References
- v
- t
- e
Monoclonal antibodies for tumors
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e